Structure-Activity Relationships and X-ray Structures Describing the Selectivity of Aminopyrazole Inhibitors for c-Jun N-terminal Kinase 3 (JNK3) over p38*
暂无分享,去创建一个
P. Lograsso | J. Habel | Y. Ling | T. Kamenecka | Y. Shin | Youseung Shin | Derek Duckett | Ted Kamenecka | Jeff Habel | Weimin Chen | Yuan Yuan Ling | Bozena Frackowiak | Rong Jiang | Xinyi Song | Philip LoGrasso | Derek R Duckett | D. Duckett | Weiming Chen | B. Frąckowiak | Rong-Hui Jiang | Xinyi Song
[1] M. Karin,et al. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. , 1993, Genes & development.
[2] H. K. Sluss,et al. Signal transduction by tumor necrosis factor mediated by JNK protein kinases , 1994, Molecular and cellular biology.
[3] L. Kuo,et al. Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. , 1996, The Journal of biological chemistry.
[4] P. Darke,et al. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. , 1994, Journal of medicinal chemistry.
[5] Jerry L. Adams,et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis , 1994, Nature.
[6] J. Woodgett,et al. The stress-activated protein kinase subfamily of c-Jun kinases , 1994, Nature.
[7] M. Karin,et al. JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain , 1994, Cell.
[8] M. Karin,et al. c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases , 1994, Molecular and cellular biology.
[9] J J Baldwin,et al. Positions of His‐64 and a bound water in human carbonic anhydrase II upon binding three structurally related inhibitors , 1994, Protein science : a publication of the Protein Society.
[10] Gennady M Verkhivker,et al. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. , 1995, Chemistry & biology.
[11] L. Tong,et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket , 1997, Nature Structural Biology.
[12] Z. Otwinowski,et al. [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[13] G. Bemis,et al. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. , 1997, Chemistry & biology.
[14] J F Davies,et al. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. , 1997, Journal of medicinal chemistry.
[15] Steven A. Carr,et al. Pyridinyl Imidazole Inhibitors of p38 Mitogen-activated Protein Kinase Bind in the ATP Site* , 1997, The Journal of Biological Chemistry.
[16] E. A. O'neill,et al. Kinetic mechanism for p38 MAP kinase. , 1997, Biochemistry.
[17] E. A. O'neill,et al. Molecular basis for p38 protein kinase inhibitor specificity. , 1998, Biochemistry.
[18] P. Caron,et al. Crystal structure of JNK3: a kinase implicated in neuronal apoptosis. , 1998, Structure.
[19] E. A. O'neill,et al. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. , 1999, Journal of Medicinal Chemistry.
[20] S. Buchwald,et al. Palladium-catalyzed amination of aryl halides and sulfonates , 1999 .
[21] S. Buchwald,et al. Simple, efficient catalyst system for the palladium-catalyzed amination of aryl chlorides, bromides, and triflates. , 2000, The Journal of organic chemistry.
[22] P. Seeburg,et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.
[23] J. Uney,et al. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[24] Haddad Jj. VX-745. Vertex Pharmaceuticals. , 2001 .
[25] J. Madwed,et al. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. , 2002, Journal of medicinal chemistry.
[26] Aina E Cohen,et al. An automated system to mount cryo-cooled protein crystals on a synchrotron beam line, using compact sample cassettes and a small-scale robot. , 2002, Journal of applied crystallography.
[27] Randy J Read,et al. Electronic Reprint Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination , 2022 .
[28] Luping Liu,et al. Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase. , 2003, Bioorganic & medicinal chemistry letters.
[29] A. Vercelli,et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia , 2003, Nature Medicine.
[30] S. Buchwald,et al. Expanding Pd-catalyzed C-N bond-forming processes: the first amidation of aryl sulfonates, aqueous amination, and complementarity with Cu-catalyzed reactions. , 2003 .
[31] J. Lisnock,et al. The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity. , 2003, Chemistry & biology.
[32] D. Zaller,et al. Structural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity , 2003, Nature Structural Biology.
[33] Pasko Rakic,et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[34] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[35] H. Kaneto,et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide , 2004, Nature Medicine.
[36] Sam-Yong Park,et al. Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125 , 2004, The EMBO journal.
[37] A. W. Schüttelkopf,et al. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.
[38] Jean-Pierre Gotteland,et al. Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. , 2005, Journal of medicinal chemistry.
[39] Michal Vieth,et al. Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy. , 2005, Journal of medicinal chemistry.
[40] Matthew R. Lee,et al. MAP Kinase p38Inhibitors: Clinical Results and an Intimate Look at Their Interactions with p38α Protein , 2005 .
[41] Britt-Marie Swahn,et al. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3. , 2005, Bioorganic & medicinal chemistry letters.
[42] C. Dominguez,et al. p38 MAP kinase inhibitors: many are made, but few are chosen. , 2005, Current opinion in drug discovery & development.
[43] Zhiqian Guo,et al. Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists. , 2005, Journal of medicinal chemistry.
[44] Yafeng Xue,et al. Design and synthesis of 2'-anilino-4,4'-bipyridines as selective inhibitors of c-Jun N-terminal kinase-3. , 2006, Bioorganic & medicinal chemistry letters.
[45] S. Schreiber,et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[46] Chaohong Sun,et al. Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. , 2006, Journal of medicinal chemistry.
[47] D. Rotstein,et al. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase. , 2006, Journal of medicinal chemistry.
[48] Eric F. Johnson,et al. Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors. , 2006, Journal of medicinal chemistry.
[49] Xiaoling Xie,et al. Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors. , 2007, Journal of medicinal chemistry.
[50] R. Angell,et al. N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. , 2007, Bioorganic & medicinal chemistry letters.
[51] Jack Snoeyink,et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids , 2007, Nucleic Acids Res..